Cite
Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
MLA
Chenggong Li, et al. “Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study.” Blood, vol. 140, Nov. 2022, pp. 4573–74. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3f2c94d0c018114adb5319ae24bc358e&authtype=sso&custid=ns315887.
APA
Chenggong Li, Xindi Wang, Zhuolin Wu, Wenjing Luo, Yinqiang Zhang, Yun Kang, Jia Xu, Zhongpei Huang, Mengyi Du, Lu Tang, Jianghua Wu, Danying Liao, Haiming Kou, Cong Lu, Huiwen Jiang, Qiuzhe Wei, Sha Ke, Jing’e Zheng, Wei Xiong, … Heng Mei. (2022). Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study. Blood, 140, 4573–4574.
Chicago
Chenggong Li, Xindi Wang, Zhuolin Wu, Wenjing Luo, Yinqiang Zhang, Yun Kang, Jia Xu, et al. 2022. “Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study.” Blood 140 (November): 4573–74. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3f2c94d0c018114adb5319ae24bc358e&authtype=sso&custid=ns315887.